Nanotechnology for understanding the tumor microenvironment heterogeneity in bone carcinoma
Source abstract
Abstract
Bone carcinoma face serious issues in its treatment owing to the complexity of the tumor microenvironment (TME) and the potential of bone metastasis. Nanotechnology provides potential strategies for addressing the intricacies and heterogeneity of tumor microenvironment in bone cancer. Recent developments in understanding the complexity of TME made it possible to precisely deliver onsite therapeutics for bone tumors, which minimized the side effects and improves the patient condition. Despite of the advancement, further exploration is needed for better therapeutic methods and preclinical research. To further enhance the detection and treatment of bone cancer, future research prospects include the progress in immunotherapies that specially targets bones and integrated therapeutic methods. This review will discuss the strategies and advancements in the diagnosis of bone carcinoma focusing on diagnostic imaging and targeted delivery of drugs for controlling and understanding of the tumor microenvironment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):359–38610.1002/ijc.29210 ↗
2. Ashraf MA, Zahid A, Ashraf S, Waquar S, Iqbal S, Malik A (2020) Implication of prophetic variables and their impulsive interplay in CA prostate patients experiencing osteo-metastasis. Anti-Cancer Agents Med Chem (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 20(17):2106–211310.2174/1871520620666200727094430 ↗
3. Fornetti J, Welm AL, Stewart SA (2018) Understanding the bone in cancer metastasis. J Bone Miner Res 33(12):2099–211310.1002/jbmr.3618 ↗
4. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT (2010) Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7(11):641–65110.1038/nrclinonc.2010.134 ↗
5. Lobo-Martins S, Ferreira AR, Mansinho A, Casimiro S, Leitzel K, Ali S, Lipton A, Costa L (2020) Impact of extraskeletal metastases on skeletal-related events in metastatic castration-resistant prostate cancer with bone metastases. Cancers 12(8):203410.3390/cancers12082034 ↗
6. Kamble S, Varamini P, Müllner M, Pelras T, Rohanizadeh R (2020) Bisphosphonate-functionalized micelles for targeted delivery of curcumin to metastatic bone cancer. Pharm Dev Technol 25(9):1118–112610.1080/10837450.2020.1798458 ↗
7. Chen X, Zhu X, Hu Y, Yuan W, Qiu X, Jiang T, Xia C, Xiong L, Li F, Gao Y (2020) EDTA-modified 17β-estradiol-laden upconversion nanocomposite for bone-targeted hormone replacement therapy for osteoporosis. Theranostics 10(7):328110.7150/thno.37599 ↗
8. Otaka A, Yamaguchi T, Saisho R, Hiraga T, Iwasaki Y (2020) Bone-targeting phospholipid polymers to solubilize the lipophilic anticancer drug. J Biomed Mater Res Part A 108(10):2090–209910.1002/jbm.a.36968 ↗
9. Li L, Huang Q, Wang C, Wang X, Xiao J, Zhang Q, Cheng Y (2016) Bone and metal targeted polymeric nanoparticles (US20150125391 A1): a patent evaluation. Expert Opin Ther Patents 26(9):987–99110.1080/13543776.2016.1212840 ↗
10. Yang Y, Zhao Z, Xie C, Zhao Y (2020) Dual-targeting liposome modified by glutamic hexapeptide and folic acid for bone metastatic breast cancer. Chem Phys Lipids 228:10488210.1016/j.chemphyslip.2020.104882 ↗
11. Miller K, Eldar-Boock A, Polyak D, Segal E, Benayoun L, Shaked Y, Satchi-Fainaro R (2011) Antiangiogenic antitumor activity of HPMA copolymer–paclitaxel–alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm 8(4):1052–106210.1021/mp200083n ↗
12. Zhu J, Huo Q, Xu M, Yang F, Li Y, Shi H, Niu Y, Liu YJN (2018) Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy. Nanoscale 10(38):18387–1839710.1039/C8NR03899F ↗
13. Pang Y, Fu Y, Li C, Wu Z, Cao W, Hu X, Sun X, He W, Cao X, Ling D (2020) Metal–organic framework nanoparticles for ameliorating breast cancer-associated osteolysis. Nano Lett 20(2):829–84010.1021/acs.nanolett.9b02916 ↗
14. Jabeen N, Rasheed R, Rafique A, Murtaza G (2019) The established nuclear medicine modalities for imaging of bone metastases. Curr Med Imaging Rev 15(9):819–83010.2174/1573405614666180327122548 ↗
15. Blackburn G, Scott TG, Bayer IS, Ghosh A, Biris AS, Biswas A (2013) Bionanomaterials for bone tumor engineering and tumor destruction. J Mater Chem B 1(11):1519–153410.1039/c3tb00536d ↗
16. Ferguson JL, Turner SP (2018) Bone cancer: diagnosis and treatment principles. Am Fam Phys 98(4):205–213
17. Rajwanshi A, Srinivas R, Upasana G (2009) Malignant small round cell tumors. J Cytol 26(1):1–1010.4103/0970-9371.54861 ↗
18. Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP (2009) Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. JBJS 91(5):1063–107210.2106/JBJS.H.00416 ↗
19. Arneth B (2019) Tumor microenvironment. Medicina 56(1):1510.3390/medicina56010015 ↗
20. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–67410.1016/j.cell.2011.02.013 ↗
21. Jahanban-Esfahlan R, Seidi K, Banimohamad-Shotorbani B, Jahanban-Esfahlan A, Yousefi B (2018) Combination of nanotechnology with vascular targeting agents for effective cancer therapy. J Cell Physiol 233(4):2982–299210.1002/jcp.26051 ↗
22. Jahanban-Esfahlan R, Seidi K, Zarghami N (2017) Tumor vascular infarction: prospects and challenges. Int J Hematol 105:244–25610.1007/s12185-016-2171-3 ↗
23. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–44410.1038/nature07205 ↗
24. Salmaninejad A, Valilou SF, Soltani A, Ahmadi S, Abarghan YJ, Rosengren RJ, Sahebkar A (2019) Tumor-associated macrophages: role in cancer development and therapeutic implications. Cell Oncol 42:591–60810.1007/s13402-019-00453-z ↗
25. Pottier C, Wheatherspoon A, Roncarati P, Longuespée R, Herfs M, Duray A, Delvenne P, Quatresooz P (2015) The importance of the tumor microenvironment in the therapeutic management of cancer. Expert Rev Anticancer Ther 15(8):943–95410.1586/14737140.2015.1059279 ↗
26. Watnick RS (2012) The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harb Perspect Med 2(12):a00667610.1101/cshperspect.a006676 ↗
27. Angell H, Galon J (2013) From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 25(2):261–26710.1016/j.coi.2013.03.004 ↗
28. Sharma G, Singh M, Sharma K, Sharma P, Mehra S (2021) Role of nanotechnology in cancer treatment. Importance & applications of nanotechnology. MedDocs Publishers 7:1–9
29. Reichert JM, Wenger JB (2008) Development trends for new cancer therapeutics and vaccines. Drug Discov Today 13(1–2):30–3710.1016/j.drudis.2007.09.003 ↗
30. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5(4):263–27410.1038/nrc1586 ↗
31. Singhal S, Nie S, Wang MD (2010) Nanotechnology applications in surgical oncology. Ann Rev Med 61(1):359–37310.1146/annurev.med.60.052907.094936 ↗
32. Chaturvedi VK, Singh A, Singh VK, Singh MP (2019) Cancer nanotechnology: a new revolution for cancer diagnosis and therapy. Curr Drug Metab 20(6):416–42910.2174/1389200219666180918111528 ↗
33. Vasir JK, Labhasetwar V (2007) Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 59(8):718–72810.1016/j.addr.2007.06.003 ↗
34. Augustine R, Al Mamun A, Hasan A, Salam SA, Chandrasekaran R, Ahmed R, Thakor AS (2021) Imaging cancer cells with nanostructures: prospects of nanotechnology driven non-invasive cancer diagnosis. Adv Coll Interface Sci 294:10245710.1016/j.cis.2021.102457 ↗
35. Caracciolo G, Vali H, Moore A, Mahmoudi MJNT (2019) Challenges in molecular diagnostic research in cancer nanotechnology. Nano Today 27:6–1010.1016/j.nantod.2019.06.001 ↗
36. Zhou Q, Zhang L, Wu H (2017) Nanomaterials for cancer therapies. Nanotechnol Rev 6(5):473–49610.1515/ntrev-2016-0102 ↗
37. Siegel RL, Miller KD, Jemal A (2018) Descriptive epidemiology. The American cancer society’s principles of oncology: Prevention to Survivorship, pp 1–1410.1002/9781119468868.ch1 ↗
38. Bussard KM, Gay CV, Mastro AM (2008) The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 27:41–5510.1007/s10555-007-9109-4 ↗
39. Balkwill FR, Capasso M, Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125(23):5591–559610.1242/jcs.116392 ↗
40. Truffi M, Sorrentino L, Corsi F (2020) Fibroblasts in the tumor microenvironment. Tumor microenvironment: Non-hematopoietic cells, pp 15–2910.1007/978-3-030-37184-5_2 ↗
41. Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30(16):R921–R92510.1016/j.cub.2020.06.081 ↗
42. Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–30610.1038/nrc3245 ↗
43. Mauri C, Bosma A (2012) Immune regulatory function of B cells. Annu Rev Immunol 30(1):221–24110.1146/annurev-immunol-020711-074934 ↗
44. Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2):263–26610.1016/j.cell.2006.01.007 ↗
45. Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40(11):2969–297510.1002/eji.201040895 ↗
46. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253–26810.1038/nri3175 ↗
47. Armulik A, Genové G, Betsholtz C (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 21(2):193–21510.1016/j.devcel.2011.07.001 ↗
48. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298–30710.1038/nature10144 ↗
49. Labelle M, Begum S, Hynes RO (2014) Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci 111(30):E3053–E306110.1073/pnas.1411082111 ↗
50. Segal BH, Giridharan T, Suzuki S, Khan ANMNH, Zsiros E, Emmons TR, Yaffe MB, Gankema AAF, Hoogeboom M, Goetschalckx I, Matlung HL, Kuijpers TW (2023) Neutrophil interactions with T cells, platelets, endothelial cells, and of course tumor cells. Immunol Rev 314(1):13–3510.1111/imr.13178 ↗
51. Morris AC, Rennie J, Rossi AG, Walsh TS (2016) Role of regulatory T cells in neutrophil function. Lancet 387:S3010.1016/S0140-6736(16)00417-7 ↗
52. Li P, Lu M, Shi J, Hua L, Gong Z, Li Q, Shultz LD, Ren G (2020) Dual roles of neutrophils in metastatic colonization are governed by the host NK cell status. Nat Commun 11(1):438710.1038/s41467-020-18125-0 ↗
53. Adrover JM, McDowell SAC, He X-Y, Quail DF, Egeblad M (2023) NETworking with cancer: the bidirectional interplay between cancer and neutrophil extracellular traps. Cancer Cell 41(3):505–52610.1016/j.ccell.2023.02.001 ↗
54. Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schall TJ (2005) Proteolytic Activation of Alternative CCR1 Ligands in Inflammation1. J Immunol 174(11):7341–735110.4049/jimmunol.174.11.7341 ↗
55. Wittamer VR, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D (2005) Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol 175(1):487–49310.4049/jimmunol.175.1.487 ↗
56. Yu X, Li C, Wang Z, Xu Y, Shao S, Shao F, Wang H, Liu J (2024) Neutrophils in cancer: dual roles through intercellular interactions. Oncogene 43(16):1163–1177
57. Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K (2019) Neoantigen-directed immune escape in lung cancer evolution. Nature 567(7749):479–48510.1038/s41586-019-1032-7 ↗
58. Jia Q, Wang A, Yuan Y, Zhu B, Long H (2022) Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol 11(1):2410.1186/s40164-022-00277-y ↗
59. Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DI, Zairis S, Abate F, Liu Z, Elliott O, Shin Y-J (2016) Clonal evolution of glioblastoma under therapy. Nat Genet 48(7):768–77610.1038/ng.3590 ↗
60. Hass R, von der Ohe J, Ungefroren H (2020) Impact of the tumor microenvironment on tumor heterogeneity and consequences for cancer cell plasticity and stemness. Cancers 12(12):371610.3390/cancers12123716 ↗
61. Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H (2017) An immune atlas of clear cell renal cell carcinoma. Cell 169(4):36–749 (e18)10.1016/j.cell.2017.04.016 ↗
62. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H (2015) Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 21(7):751–75910.1038/nm.3886 ↗
63. Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi AC, van den Braber M, Rozeman EA, Haanen JB, Blank CU (2019) Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176(4):775–789 (e18)10.1016/j.cell.2018.11.043 ↗
64. Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, Nainys J, Wu K, Kiseliovas V, Setty M (2018) Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174(5):1293–1308 (e36)10.1016/j.cell.2018.05.060 ↗
65. Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, Sirven P, Magagna I, Fuhrmann L, Bernard C (2018) Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33(3):463–479 (e10)10.1016/j.ccell.2018.01.011 ↗
66. Bailey C, Black JR, Reading JL, Litchfield K, Turajlic S, McGranahan N, Jamal-Hanjani M, Swanton C (2021) Tracking cancer evolution through the disease course. Cancer Discov 11(4):916–93210.1158/2159-8290.CD-20-1559 ↗
67. Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8(328):328rv4-328rv410.1126/scitranslmed.aad7118 ↗
68. Gajewski TF, Schreiber H, Fu Y-X (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014–102210.1038/ni.2703 ↗
69. Batlle E, Massagué J (2019) Transforming growth factor-β signaling in immunity and cancer. Immunity 50(4):924–94010.1016/j.immuni.2019.03.024 ↗
70. Ding R, Liu S, Wang S, Chen H, Wang F, Xu Q, Zhu L, Dong X, Gu Y, Zhang X (2021) Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells. Theranostics 11(10):495710.7150/thno.55075 ↗
71. Montenegro F, Indraccolo S (2020) Metabolism in the tumor microenvironment. Tumor Microenvironment: State of the Science, pp 1–1110.1007/978-3-030-44518-8_1 ↗
72. Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T (2021) Germline genetic contribution to the immune landscape of cancer. Immunity 54(2):367–386 (e8)10.1016/j.immuni.2021.01.011 ↗
73. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Elizabeth AY, Schenk EL, Tan W, Zee A (2020) Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182(5):1232–1251 (e22)10.1016/j.cell.2020.07.017 ↗
74. McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168(4):613–62810.1016/j.cell.2017.01.018 ↗
75. Kumar S, Warrell J, Li S, McGillivray PD, Meyerson W, Salichos L, Harmanci A, Martinez-Fundichely A, Chan CW, Nielsen MM (2020) Passenger mutations in more than 2,500 cancer genomes: overall molecular functional impact and consequences. Cell 180(5):915–927 (e16)10.1016/j.cell.2020.01.032 ↗
76. Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KC, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB (2020) Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183(3):818–834 (e13)10.1016/j.cell.2020.09.015 ↗
77. Noble R, Burley JT, Le Sueur C, Hochberg ME (2020) When, why and how tumour clonal diversity predicts survival. Evol Appl 13(7):1558–156810.1111/eva.13057 ↗
78. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545(7655):446–45110.1038/nature22364 ↗
79. Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11(6):411–42510.1038/nrc3055 ↗
80. Croucher PI, McDonald MM, Martin TJ (2016) Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer 16(6):373–38610.1038/nrc.2016.44 ↗
81. Body J-J, Casimiro S, Costa L (2015) Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol 12(6):340–35610.1038/nrurol.2015.90 ↗
82. Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289(5484):1508–151410.1126/science.289.5484.1508 ↗
83. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG (2012) Treating metastatic cancer with nanotechnology. Nat Rev Cancer 12(1):39–5010.1038/nrc3180 ↗
84. Vinay R, KusumDevi V (2016) Potential of targeted drug delivery system for the treatment of bone metastasis. Drug Deliv 23(1):21–2910.3109/10717544.2014.913325 ↗
85. Carbone EJ, Rajpura K, Allen BN, Cheng E, Ulery BD (2017) Lo KWH Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties. Nanomedicine: Nanotechnol Biol Med 13(1):37–4710.1016/j.nano.2016.08.015 ↗
86. Wang D, Miller SC, Kopečková P, Kopeček J (2005) Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev 57(7):1049–107610.1016/j.addr.2004.12.011 ↗
87. Cheng H, Chawla A, Yang Y, Li Y, Zhang J, Jang HL, Khademhosseini A (2017) Development of nanomaterials for bone-targeted drug delivery. Drug Discov Today 22(9):1336–135010.1016/j.drudis.2017.04.021 ↗
88. van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJ, Lammers T (2019) Smart cancer nanomedicine. Nat Nanotechnol 14(11):1007–101710.1038/s41565-019-0567-y ↗
89. Zhou X, Yan N, Cornel EJ, Cai H, Xue S, Xi H, Fan Z, He S, Du J (2021) Bone-targeting polymer vesicles for simultaneous imaging and effective malignant bone tumor treatment. Biomaterials 269:12034510.1016/j.biomaterials.2020.120345 ↗
90. Gu W, Wu C, Chen J, Xiao Y (2013) Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration. Int J Nanomedicine 8:2305–231710.2147/IJN.S44393 ↗
91. Russell R, Rogers M (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25(1):97–10610.1016/S8756-3282(99)00116-7 ↗
92. Lipton A (2005) New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther 5(6):817–83210.1517/14712598.5.6.817 ↗
93. Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12(20):6222s–6230s10.1158/1078-0432.CCR-06-0843 ↗
94. Coleman RE, McCloskey EV (2011) Bisphosphonates in oncology. Bone 49(1):71–7610.1016/j.bone.2011.02.003 ↗
95. Gnant M (2009) Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 9(7):824–83310.2174/156800909789760267 ↗
96. Hurst M, Noble S (1999) Clodronate: a review of its use in breast cancer. Drugs Aging 15:143–16710.2165/00002512-199915020-00007 ↗
97. Meli M, Rausa L, Panasci L, Sandor V, Melnychuk D, Atkins C, Diel I, Costa S, Kaufmann M (1998) Clodronate in metastatic breast cancer. N Engl J Med 339:1940–194110.1056/NEJM199812243392614 ↗
98. Lipton A (2008) Emerging role of bisphosphonates in the clinic—antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34:S25–S3010.1016/j.ctrv.2008.03.008 ↗
99. Meulenbeld H, Van Werkhoven E, Coenen J, Creemers G-J, Loosveld O, De Jong P, ten Tije AJ, Fosså S, Polee M, Gerritsen W (2012) Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic castration resistant prostate cancer (CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer 48(16):2993–300010.1016/j.ejca.2012.05.014 ↗
100. Kim SW, Kim JS, Papadopoulos J, Choi HJ, He J, Maya M, Langley RR, Fan D, Fidler IJ, Kim S-J (2011) Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol 11(7):862–87210.1016/j.intimp.2011.01.004 ↗